FDA BACKS PAPER NDA POLICY

被引：0

|

作者：

不详

机构：

来源：

AMERICAN PHARMACY | 1981年 / 21卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：7 / 8

页数：2

相关论文

共 50 条

[1] DRUG POLICY - FDA PANEL BACKS INTERLEUKIN-2
CULLITON, BJ
NATURE, 1992, 355 (6358) : 287 - 287
[2] PAPER NDA UPDATE
HYMAN, PM
FOOD AND DRUG LAW JOURNAL, 1981, 36 (06): : 303 - 313
[3] FDA backs rosiglitazone - with warnings
Tanne, Janice Hopkins
BRITISH MEDICAL JOURNAL, 2007, 335 (7613): : 223 - 223
[4] Congress backs FDA fees and policy changes but largely sidesteps information issues
Wechsler, J
FORMULARY, 1997, 32 (07) : 756 - &
[5] FDA to continue review of Relenza NDA
不详
DRUG NEWS & PERSPECTIVES, 1999, 12 (03) : 182 - 182
[6] US FDA backs olestra
Ault, A
LANCET, 1998, 351 (9120): : 1942 - 1942
[7] Combidex NDA accepted for FDA review
不详
DRUG NEWS & PERSPECTIVES, 2000, 13 (01) : 64 - 64
[8] NDA application for Temodal submitted to FDA
不详
DRUG NEWS & PERSPECTIVES, 1998, 11 (06) : 379 - 379
[9] Best practices for communication between FDA and applicants during the NDA review cycle: A PhRMA white paper
Cocchetto, David M.
Stotka, Jennifer L.
Zezza, Diane
Hassall, Thomas H.
Brophy, Gregory
Peterson, Donna
DRUG INFORMATION JOURNAL, 2008, 42 (01): : 3 - 8
[10] Best Practices for Communication between FDA and Applicants during the NDA Review Cycle: A PhRMA White Paper
David M. Cocchetto
Jennifer L. Stotka
Diane Zezza
Thomas H. Hassall
Gregory Brophy
Donna Peterson
Drug information journal : DIJ / Drug Information Association, 2008, 42 (1): : 3 - 8

← 1 2 3 4 5 →